Trial Details 30 Total Sites

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.

phase

Phase 2

status

Recruiting

enrollment

150

score

27

start date

2020-07-30

last updated

2021-12-22

biomarkers

N/A

Dallas, Texas
facility
Mary Crowley Cancer Research Center ( Site 0107)
1 facility
Recruiting
Nashville, Tennessee
facility
Monroe Carell Jr. Children's Hospital at Vanderbilt ( Site 0102)
1 facility
Recruiting
Cleveland, Ohio
facility
Cleveland Clinic ( Site 0119)
1 facility
Recruiting
Aurora, Colorado
facility
Children's Hospital of Colorado ( Site 0110)
1 facility
Recruiting
Buenos Aires, Argentina
facility
Hospital de Niños Ricardo Gutiérrez ( Site 0125)
1 facility
Recruiting
Moscow, Russia
facility
Dmitry Rogachev National Research Center ( Site 0550)
1 facility
Recruiting
St. Petersburg, Russia
facility
St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0554)
1 facility
Recruiting
St. Petersburg, Russia
facility
Clinical Research Center of specialized types medical care-Oncology ( Site 0553)
1 facility
Recruiting
Cape Town, South Africa
facility
Cancercare Rondebosch Oncology ( Site 0575)
1 facility
Recruiting
Rome, Italy
facility
IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0410)
1 facility
Recruiting
Brisbane, Australia
facility
Queensland Children s Hospital ( Site 0804)
1 facility
Recruiting
Soweto, South Africa
facility
Wits Clinical Research ( Site 0579)
1 facility
Recruiting